Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan and Carboplatin in Relapsed Ovarian Cancer
NCT00170625Phase 2Completed
- Sponsor
- NOGGO
- Start
- Jun 2004
- Primary completion
- Aug 2005
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of topotecan in ovarian cancer (2 arms), sponsored by NOGGO. Primary endpoint: Dose Limiting Toxicity. Started Jun 2004; status: completed.
02
Drugs
topotecan
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00170625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00170625.